Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

306 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes.
Julià A, Tortosa R, Hernanz JM, Cañete JD, Fonseca E, Ferrándiz C, Unamuno P, Puig L, Fernández-Sueiro JL, Sanmartí R, Rodríguez J, Gratacós J, Dauden E, Sánchez-Carazo JL, López-Estebaranz JL, Moreno-Ramírez D, Queiró R, Montilla C, Torre-Alonso JC, Pérez-Venegas JJ, Vanaclocha F, Herrera E, Muñoz-Fernández S, González C, Roig D, Erra A, Acosta I, Fernández-Nebro A, Zarco P, Alonso A, López-Lasanta M, García-Montero A, Gelpí JL, Absher D, Marsal S. Julià A, et al. Among authors: dauden e. Hum Mol Genet. 2012 Oct 15;21(20):4549-57. doi: 10.1093/hmg/dds295. Epub 2012 Jul 19. Hum Mol Genet. 2012. PMID: 22814393
[Consensus document on the evaluation and treatment of moderate-to-severe psoriasis. Spanish psoriasis group of the Spanish Academy of Dermatology and Venereology].
Puig L, Bordas X, Carrascosa JM, Daudén E, Ferrándiz C, Hernanz JM, López-Estebaranz JL, Moreno JC, Sánchez-Carazo JL, Vanaclocha F, Vázquez-Veiga H; Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. Puig L, et al. Among authors: dauden e. Actas Dermosifiliogr. 2009 May;100(4):277-86. Actas Dermosifiliogr. 2009. PMID: 19463230 Spanish.
[Spanish evidence-based guidelines on the treatment of moderate-to-severe psoriasis with biologic agents].
Puig L, Carrascosa JM, Daudén E, Sánchez-Carazo JL, Ferrándiz C, Sánchez-Regaña M, García-Bustinduy M, Bordas X, Moreno JC, Hernanz JM, Laguarda S, García-Patos V; Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. Puig L, et al. Among authors: dauden e. Actas Dermosifiliogr. 2009 Jun;100(5):386-413. Actas Dermosifiliogr. 2009. PMID: 19558918 Spanish.
[Guidelines on the use of methotrexate in psoriasis].
Carretero G, Puig L, Dehesa L, Carrascosa JM, Ribera M, Sánchez-Regaña M, Daudén E, Vidal D, Alsina M, Muñoz-Santos C, López-Estebaranz JL, Notario J, Ferrandiz C, Vanaclocha F, García-Bustinduy M, Taberner R, Belinchón I, Sánchez-Carazo J, Moreno JC; Grupo de Psoriasis de la AEDV. Carretero G, et al. Among authors: dauden e. Actas Dermosifiliogr. 2010 Sep;101(7):600-13. Actas Dermosifiliogr. 2010. PMID: 20858386 Spanish.
[Narrowband UV-B, monochromatic excimer laser, and photodynamic therapy in psoriasis: a consensus statement of the Spanish Psoriasis Group].
Carrascosa JM, López-Estebaranz JL, Carretero G, Daudén E, Ferrándiz C, Vidal D, Belinchón I, Sánchez-Regaña M, Puig L; Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. Carrascosa JM, et al. Among authors: dauden e. Actas Dermosifiliogr. 2011 Apr;102(3):175-86. doi: 10.1016/j.ad.2010.11.002. Actas Dermosifiliogr. 2011. PMID: 21310368 Free article. Spanish.
[BIOBADADERM, the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology: first report].
Rivera R, García-Doval I, Carretero G, Daudén E, Sánchez-Carazo J, Ferrándiz C, Herrera E, Alsina M, Ferrán M, López-Estebaranz JL, Gómez F, Herranz JM, Carrascosa JM, Vanaclocha F; miembros del grupo BIOBADADERM. Rivera R, et al. Among authors: dauden e. Actas Dermosifiliogr. 2011 Mar;102(2):132-41. doi: 10.1016/j.ad.2010.10.016. Epub 2011 Mar 4. Actas Dermosifiliogr. 2011. PMID: 21377137 Free article. Spanish.
[Clinical characteristics and disease course in patients treated with efalizumab following suspension of marketing authorization by the European medicines agency: a multicenter observational study].
Morell L, Carrascosa JM, Ferrándiz C, García-Bustinduy M, Fonseca E, Carretero G, Daudén E, Marrón SE, López-Estebaranz JL, Ferrán M, Sánchez-Regaña M, Muñoz-Santos C, Belinchón I, Puig L; Grupo Español de Psoriasis. Morell L, et al. Among authors: dauden e. Actas Dermosifiliogr. 2011 Jun;102(5):354-64. doi: 10.1016/j.ad.2010.12.013. Epub 2011 Apr 29. Actas Dermosifiliogr. 2011. PMID: 21530928 Free article. Spanish.
306 results